Version history

{
  "session_id": "sess_b7f886d9-da3f-4e0d-a8a8-9c262e268796_task_66f1207e_recon",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "scidex.core.llm.complete",
  "action": "assess",
  "content": "Domain expert assessment for analysis b7f886d9-da3f-4e0d-a8a8-9c262e268796: m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra\n\nThe practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a translational biomarker or intervention point.\n\nFor model systems, prioritize human iPSC-derived disease-relevant cells, co-culture or organoid systems only when the question explicitly requires cross-cell interaction, and mouse models only for organism-level timing or NMJ/vascular phenotypes. Biomarkers should be proximal to mechanism: transcriptional module activity, protein localization, lipid or RNA-modification state, spatial vascular coupling, or motor-unit integrity depending on the gap.\n\nThe development risk is moderate. The question is specific enough to generate falsifiable work, and it is anchored to Integration of multi-omics summary data reveals the role of N6-methyladenosine in Parkinson's disease. The risk is that therapeutic tractability may lag mechanistic clarity: even if m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics is causal, the safest intervention point may be an upstream regulator, a cell-state transition, or a biomarker-guided patient subset rather than the named entity itself.",
  "tokens_used": "408",
  "persona_id": "persona-domain_expert"
}